HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marcel Levi Selected Research

Thromboplastin (Tissue Factor)

6/2021Pathophysiology of Coagulopathy in Hematological Malignancies and in COVID-19.
7/2012Infection and inflammation as risk factors for thrombosis and atherosclerosis.
1/2012Relative Tissue Factor Deficiency Attenuates Ventilator-Induced Coagulopathy but Does Not Protect against Ventilator-Induced Lung Injury in Mice.
6/2011The effect of inflammation on coagulation and vice versa.
6/2010Disseminated intravascular coagulation in infectious disease.
7/2008Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
2/2008Metabolic modulation of inflammation-induced activation of coagulation.
6/2007Procoagulant and fibrinolytic activity in cerebrospinal fluid from adults with bacterial meningitis.
3/2007Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
11/2006Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marcel Levi Research Topics

Disease

67Sepsis (Septicemia)
01/2022 - 01/2002
52Inflammation (Inflammations)
02/2022 - 05/2002
49Hemorrhage
08/2019 - 11/2002
46Disseminated Intravascular Coagulation
01/2022 - 01/2002
30Thrombosis (Thrombus)
10/2021 - 01/2002
29Infections
10/2021 - 04/2002
23Pneumonia (Pneumonitis)
01/2021 - 04/2002
17COVID-19
01/2022 - 01/2020
14Neoplasms (Cancer)
06/2021 - 03/2002
13Thrombocytopenia (Thrombopenia)
10/2022 - 03/2002
13Wounds and Injuries (Trauma)
01/2018 - 04/2005
12Critical Illness (Critically Ill)
01/2021 - 01/2006
11Pneumococcal Pneumonia
03/2015 - 04/2002
11Acute Lung Injury
01/2013 - 05/2003
10Endotoxemia
09/2012 - 10/2002
9Venous Thromboembolism
06/2021 - 03/2002
9Lung Injury
11/2017 - 10/2006
7Hereditary Angioedemas
01/2022 - 10/2005
7Thrombotic Microangiopathies
07/2020 - 11/2003
7Ischemia
01/2017 - 03/2002
7Acute Coronary Syndrome
12/2011 - 02/2002
6Venous Thrombosis (Deep-Vein Thrombosis)
10/2022 - 01/2002
6Angioedema
01/2020 - 04/2006
6Atrial Fibrillation
09/2011 - 02/2004
5Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
06/2021 - 07/2008
5Delirium
10/2014 - 05/2007
5Stroke (Strokes)
09/2009 - 02/2004
4Thromboembolism
01/2020 - 02/2004
4Human Influenza (Influenza)
10/2011 - 11/2006
4Hyperglycemia
07/2008 - 02/2006
4Peritonitis
05/2007 - 06/2004
3Intracranial Sinus Thrombosis (Sinus Thrombosis)
01/2022 - 01/2021
3Hemophilia A (Haemophilia)
07/2020 - 04/2005
3Acquired angioedema
01/2019 - 04/2006
3Cardiovascular Diseases (Cardiovascular Disease)
06/2014 - 05/2008
3Melioidosis
01/2013 - 03/2010
3Cognitive Dysfunction
01/2011 - 10/2007
3Ischemic Stroke
09/2009 - 09/2007

Drug/Important Bio-Agent (IBA)

53AnticoagulantsIBA
01/2022 - 11/2002
40Dacarbazine (DIC)FDA LinkGeneric
01/2022 - 01/2002
33Protein CIBA
11/2017 - 06/2003
32FibrinIBA
06/2021 - 12/2002
28ThrombinFDA Link
03/2015 - 03/2002
25AntithrombinsIBA
01/2020 - 06/2004
22Thromboplastin (Tissue Factor)IBA
06/2021 - 02/2002
20Hemostatics (Antihemorrhagics)IBA
07/2020 - 05/2002
19Heparin (Liquaemin)FDA LinkGeneric
01/2021 - 01/2002
14CytokinesIBA
06/2021 - 05/2002
14Blood Coagulation Factors (Coagulation Factor)IBA
06/2019 - 08/2003
12Proteins (Proteins, Gene)FDA Link
06/2019 - 04/2003
9fibrin fragment D (D-dimer)IBA
02/2022 - 04/2003
8Interleukin-6 (Interleukin 6)IBA
02/2022 - 03/2004
8Pharmaceutical PreparationsIBA
01/2020 - 01/2002
8Factor VIIa (Activated Factor VII)IBA
11/2010 - 01/2003
7Plasminogen InactivatorsIBA
03/2015 - 08/2003
7recombinant FVIIa (rFVIIa)FDA Link
11/2010 - 11/2002
6ThrombomodulinIBA
02/2022 - 07/2010
6FibrinolysinFDA Link
10/2019 - 03/2004
6Fibrin Fibrinogen Degradation ProductsIBA
10/2011 - 04/2003
6drotrecogin alfa activated (Xigris)FDA Link
01/2011 - 10/2005
5Biomarkers (Surrogate Marker)IBA
02/2022 - 02/2005
5PlasminogenIBA
10/2019 - 08/2003
5danaparoid (Orgaran)FDA Link
11/2017 - 01/2009
5Plasminogen Activators (Plasminogen Activator)IBA
10/2012 - 04/2002
5Prothrombin (Factor II)IBA
05/2011 - 10/2005
4ChAdOx1 nCoV-19IBA
01/2022 - 01/2021
4Biological ProductsIBA
06/2021 - 09/2007
4von Willebrand FactorIBA
07/2020 - 04/2008
4antithrombin III-protease complexIBA
01/2020 - 04/2003
4Fibrinogen (Factor I)FDA Link
01/2020 - 04/2003
4lipoprotein-associated coagulation inhibitor (TFPI)IBA
11/2017 - 08/2002
4Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
01/2016 - 03/2002
4Peptide Hydrolases (Proteases)FDA Link
01/2016 - 01/2004
4LipopolysaccharidesIBA
01/2013 - 09/2008
4CoagulantsIBA
08/2012 - 05/2006
4Plasminogen Activator Inhibitor 1IBA
07/2012 - 08/2003
4Antifibrinolytic Agents (Antifibrinolytics)IBA
06/2012 - 01/2006
4Vitamin KFDA Link
10/2010 - 05/2008
4EndotoxinsIBA
07/2008 - 06/2003
3VaccinesIBA
10/2022 - 10/2021
3tocilizumab (atlizumab)FDA Link
01/2022 - 01/2020
3Messenger RNA (mRNA)IBA
01/2022 - 08/2003
3Complement System Proteins (Complement)IBA
10/2019 - 10/2007
3Peptides (Polypeptides)IBA
11/2017 - 10/2002
3Anti-Bacterial Agents (Antibiotics)IBA
01/2017 - 01/2010
3Factor Xa InhibitorsIBA
08/2016 - 11/2002
3Enoxaparin (Lovenox)FDA LinkGeneric
03/2016 - 08/2003
3Endothelial Protein C ReceptorIBA
05/2014 - 09/2012
3factor V LeidenIBA
07/2013 - 01/2010
3Interleukin-8 (Interleukin 8)IBA
10/2012 - 05/2007
3Proteinase-Activated ReceptorsIBA
09/2012 - 03/2008
3Tissue Plasminogen Activator (Alteplase)FDA Link
07/2012 - 01/2006
3Saline SolutionIBA
10/2011 - 06/2004
3Warfarin (Coumadin)FDA LinkGeneric
09/2011 - 07/2005
3Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
03/2010 - 04/2002

Therapy/Procedure

26Therapeutics
10/2021 - 03/2002
5Drug Therapy (Chemotherapy)
06/2021 - 03/2002
5Artificial Respiration (Mechanical Ventilation)
12/2012 - 09/2005
4Critical Care (Surgical Intensive Care)
01/2020 - 09/2005
3Stents
12/2011 - 01/2009